On March 28, the US Food and Drug Administration (FDA) approved durvalumab with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle-invasive bladder cancer.

For more information, read the FDA announcement.

Posted on 3/28/2025